976 related articles for article (PubMed ID: 20223286)
1. Formulation strategy and use of excipients in pulmonary drug delivery.
Pilcer G; Amighi K
Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
[TBL] [Abstract][Full Text] [Related]
2. The nanoscale in pulmonary delivery. Part 2: formulation platforms.
Rogueda PG; Traini D
Expert Opin Drug Deliv; 2007 Nov; 4(6):607-20. PubMed ID: 17970664
[TBL] [Abstract][Full Text] [Related]
3. Dry powder inhaler formulation.
Telko MJ; Hickey AJ
Respir Care; 2005 Sep; 50(9):1209-27. PubMed ID: 16122404
[TBL] [Abstract][Full Text] [Related]
4. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
Minne A; Boireau H; Horta MJ; Vanbever R
Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
[TBL] [Abstract][Full Text] [Related]
5. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
Lau M; Young PM; Traini D
Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
[TBL] [Abstract][Full Text] [Related]
6. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids.
Hadinoto K; Phanapavudhikul P; Kewu Z; Tan RB
Int J Pharm; 2007 Mar; 333(1-2):187-98. PubMed ID: 17084567
[TBL] [Abstract][Full Text] [Related]
7. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin.
Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
Int J Pharm; 2010 Apr; 389(1-2):74-85. PubMed ID: 20085803
[TBL] [Abstract][Full Text] [Related]
8. Effervescent dry powder for respiratory drug delivery.
Ely L; Roa W; Finlay WH; Löbenberg R
Eur J Pharm Biopharm; 2007 Mar; 65(3):346-53. PubMed ID: 17156987
[TBL] [Abstract][Full Text] [Related]
9. Formation, characterization, and fate of inhaled drug nanoparticles.
Zhang J; Wu L; Chan HK; Watanabe W
Adv Drug Deliv Rev; 2011 May; 63(6):441-55. PubMed ID: 21118707
[TBL] [Abstract][Full Text] [Related]
10. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants.
Cheow WS; Ng ML; Kho K; Hadinoto K
Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560
[TBL] [Abstract][Full Text] [Related]
11. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
12. Particle engineering techniques for inhaled biopharmaceuticals.
Shoyele SA; Cawthorne S
Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1009-29. PubMed ID: 17005293
[TBL] [Abstract][Full Text] [Related]
13. Novel dry powder inhalation system based on dispersion of lyophilisates.
Claus S; Schoenbrodt T; Weiler C; Friess W
Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
[TBL] [Abstract][Full Text] [Related]
14. Dry powder inhalers for pulmonary drug delivery.
Frijlink HW; De Boer AH
Expert Opin Drug Deliv; 2004 Nov; 1(1):67-86. PubMed ID: 16296721
[TBL] [Abstract][Full Text] [Related]
15. Effect of milling and sieving on functionality of dry powder inhalation products.
Steckel H; Markefka P; teWierik H; Kammelar R
Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle formulations in pulmonary drug delivery.
Bailey MM; Berkland CJ
Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
[TBL] [Abstract][Full Text] [Related]
17. Development and testing of particulate formulations for the nasal delivery of antibodies.
Kaye RS; Purewal TS; Alpar OH
J Control Release; 2009 Apr; 135(2):127-35. PubMed ID: 19059291
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
Karimi K; Katona G; Csóka I; Ambrus R
J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
[TBL] [Abstract][Full Text] [Related]
19. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
[TBL] [Abstract][Full Text] [Related]
20. Study on the Pulmonary Delivery System of Apigenin-Loaded Albumin Nanocarriers with Antioxidant Activity.
Pápay ZE; Kósa A; Böddi B; Merchant Z; Saleem IY; Zariwala MG; Klebovich I; Somavarapu S; Antal I
J Aerosol Med Pulm Drug Deliv; 2017 Aug; 30(4):274-288. PubMed ID: 28282259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
